アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

ajanta pharma usa inc. - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 0.25 mg - risperidone tablets are indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies (14.1)] . monotherapy risperidone tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see clinical studies (14.2)] .  adjunctive therapy risperidone tablets adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see clinical studies (14.3)] . risperidone tablets are indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, te

カナダ - 英語 - Health Canada

dominion pharmacal - risperidone (risperidone tartrate) - solution - 1mg - risperidone (risperidone tartrate) 1mg - atypical antipsychotics

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

unit dose services - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 1 mg - risperidone tablets are indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies (14.1)] . monotherapy risperidone tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see clinical studies (14.2)] . adjunctive therapy risperidone tablets adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [ see clinical studies (14.3)]. risperidone tablets are indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, tem

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

contract pharmacy services-pa - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 0.25 mg - adults risperidone (risperidone) is indicated for the acute and maintenance treatment of schizophrenia [see clinical studies (14.1)]. adolescents due to janssen pharmaceuticals corporation's marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with schizophrenia. pediatric use information for the treatment of pediatric patients with schizophrenia, 13 to 17 years of age, is approved for janssen pharmaceuticals corporation's risperidone drug products. monotherapy adults and pediatrics risperidone is indicated for the short-term treatment of acute manic or mixed episodes associated with bipolar i disorder in adults [see clinical studies (14.2)]. due to janssen pharmaceuticals corporation's marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with bipolar mania. pediatric use information for the treatment of pediatric patients with bipolar mania, 10 to 17 years of age, is approved for janssen pharmaceuticals corporation's risperidone

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

direct rx - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 1 mg - 1.1 schizophrenia risperidone (risperidone) is indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see clinical studies ( 14.1)]. 1.2 bipolar mania monotherapy risperidone is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see clinical studies ( 14.2)]. adjunctive therapy risperidone adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see clinical studies ( 14.3)]. 1.3 irritability associated with autistic disorder pediatrics risperidone is indicated for the treatment of irritability assoc

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

tya pharmaceuticals - risperidone (unii: l6uh7zf8hc) (risperidone - unii:l6uh7zf8hc) - risperidone 0.5 mg - risperidone (risperidone) is indicated for the treatment of schizophrenia. efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see ]. clinical studies ( ) 14.1 monotherapy risperidone is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see ]. clinical studies ( ) 14.2 adjunctive therapy risperidone adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with bipolar i disorder. efficacy was established in one short-term trial in adults [see ]. clinical studies ( )

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: lactose monohydrate; titanium dioxide; magnesium stearate; maize starch; microcrystalline cellulose; hypromellose; hyprolose; indigo carmine aluminium lake; macrogol 8000; iron oxide yellow - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment of behavioural disturbances in dementia. treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. treatment of behavioural disorders associated with autism in children and adolescents.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risperidone, quantity: 3 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; iron oxide yellow; magnesium stearate; hypromellose; maize starch; titanium dioxide; macrogol 8000; lactose monohydrate - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment of behavioural disturbances in dementia. treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. treatment of behavioural disorders associated with autism in children and adolescents.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risperidone, quantity: 2 mg - tablet, film coated - excipient ingredients: titanium dioxide; microcrystalline cellulose; lactose monohydrate; hypromellose; magnesium stearate; hyprolose; sunset yellow fcf aluminium lake; maize starch; macrogol 8000 - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment of behavioural disturbances in dementia. treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. treatment of behavioural disorders associated with autism in children and adolescents.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risperidone, quantity: 1 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hyprolose; titanium dioxide; maize starch; magnesium stearate; hypromellose; lactose monohydrate; macrogol 8000 - treatment of schizophrenia and related psychoses. short-term treatment of acute mania associated with bipolar i disorder. treatment of behavioural disturbances in dementia. treatment of conduct and other disruptive disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent. treatment of behavioural disorders associated with autism in children and adolescents.